Anticancer effects of lactoferrin: Underlying mechanisms and future trends in cancer therapy

Nutrition Reviews

Volumn 72, Issue 12, 2014, Pages 763-773

  Zhang, Yunlei ^a,b   Lima, Cristovao F ^a   Rodrigues, Ligia R ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Cancer therapy; Cytotoxicity; Gene; Lactoferrin; Mechanisms; Protein

Indexed keywords

IRON; LACTOFERRIN; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CELL CYCLE ARREST; CELL MEMBRANE; CYTOTOXICITY; DRUG MECHANISM; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; NEOPLASM; REGULATORY MECHANISM; TOXICITY; CELL CYCLE CHECKPOINT; CELLS; CHEMOPROPHYLAXIS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL MEMBRANE; CELLS; CHEMOPREVENTION; GENE EXPRESSION; GENETIC VARIATION; HUMANS; LACTOFERRIN; NEOPLASMS;

EID: 84913534042     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12155     Document Type: Article

References (90)

1. Farnaud S, Evans RW. Lactoferrin - a multifunctional protein with antimicrobial properties. Mol Immunol. 2003;40:395-405.
2. Rodrigues L, Teixeira J, Schmitt F, etal. Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr. 2009;49:203-217.
3. Masson PL, Heremans JF. Lactoferrin in milk from different species. Comp Biochem Physiol B. 1971;39:119-129.
4. Adlerova L, Bartoskova A, Faldyna M. Lactoferrin: a review. Veterinarni Medicina. 2008;53:457-468.
5. Gibson RJ, Bowen JM. Biomarkers of regimen-related mucosal injury. Cancer Treat Rev. 2011;37:487-493.
6. Zhou N, Tieleman DP, Vogel HJ. Molecular dynamics simulations of bovine lactoferricin: turning a helix into a sheet. Biometals. 2004;17:217-223.
7. Hoedt E, Hardivillé S, Mariller C, etal. Discrimination and evaluation of lactoferrin and delta-lactoferrin gene expression levels in cancer cells and under inflammatory stimuli using TaqMan real-time PCR. Biometals. 2010;23:441-452.
8. Benaïssa M, Peyrat JP, Hornez L, etal. Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J Cancer. 2005;114:299-306.
9. Zhou Y, Zeng Z, Zhang W, etal. Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer. 2008;123:2065-2072.
10. Breton M, Mariller C, Benaïssa M, etal. Expression of delta-lactoferrin induces cell cycle arrest. Biometals. 2004;17:325-329.
11. Onishi J, Roy MK, Juneja LR, etal. A lactoferrin-derived peptide with cationic residues concentrated in a region of its helical structure induces necrotic cell death in a leukemic cell line (HL-60). J Pept Sci. 2008;14:1032-1038.
12. Roy MK, Kuwabara Y, Hara K, etal. Peptides from the N-terminal end of bovine lactoferrin induce apoptosis in human leukemic (HL-60) cells. J Dairy Sci. 2002;85:2065-2074.
13. Sakai T, Banno Y, Kato Y, etal. Pepsin-digested bovine lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral cancer cells. J Pharmacol Sci. 2005;98:41-48.
14. Damiens E, El Yazidi I, Mazurier J, etal. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem. 1999;74:486-498.
15. Furlong SJ, Mader JS, Hoskin DW. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol Rep. 2006;15:1385-1390.
16. Xiao Y, Monitto CL, Minhas KM, etal. Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res. 2004;10:8683-8686.
17. Mader JS, Salsman J, Conrad DM, etal. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther. 2005;4:612-624.
18. Yang N, Strøm MB, Mekonnen SM, etal. The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J Pept Sci. 2004;10:37-46.
19. Duarte DC, Nicolau A, Teixeira JA, etal. The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci. 2011;94:66-76.
20. Teng CT, Gladwell W, Beard C, etal. Lactoferrin gene expression is estrogen responsive in human and rhesus monkey endometrium. Mol Hum Reprod. 2002;8:58-67.
21. Teng C. Mouse lactoferrin gene: a marker for estrogen and epidermal growth factor. Environ Health Perspect. 1995;103:17-20.
22. Liu Y, Yang N, Teng CT. COUP-TF acts as a competitive repressor for estrogen receptor-mediated activation of the mouse lactoferrin gene. Mol Cell Biol. 1993;13:1836-1846.
23. Zheng J, Ather JL, Sonstegard TS, etal. Characterization of the infection-responsive bovine lactoferrin promoter. Gene. 2005;353:107-117.
24. Li Y, Limmon GV, Imani F, etal. Induction of lactoferrin gene expression by innate immune stimuli in mouse mammary epithelial HC-11 cells. Biochimie. 2009;91:58-67.
25. Close MJ, Howlett AR, Roskelley CD, etal. Lactoferrin expression in mammary epithelial cells is mediated by changes in cell shape and actin cytoskeleton. J Cell Sci. 1997;110:2861-2871.
26. Liao Y, Du X, Lönnerdal B. miR-214 regulates lactoferrin expression and pro-apoptotic function in mammary epithelial cells. J Nutr. 2010;140:1552-1556.
27. Kabat GC, O'Leary ES, Gammon MD, etal. Estrogen metabolism and breast cancer. Epidemiology. 2006;17:80-88.
28. Muti P, Bradlow HL, Micheli A, etal. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11:635-640.
29. de Martel C, Ferlay J, Franceschi S, etal. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607-615.
30. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17:394-398.
31. Furmanski P, Li ZP, Fortuna MB, etal. Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that possess ribonuclease activity and lack iron-binding capacity. J Exp Med. 1989;170:415-429.
32. Teng C, Gladwell W, Raphiou I, etal. Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals. 2004;17:317-323.
33. Panella TJ, Liu YH, Huang AT, etal. Polymorphism and altered methylation of the lactoferrin gene in normal leukocytes, leukemic cells, and breast cancer. Cancer Res. 1991;51:3037-3043.
34. Liu LH, Gladwell W, Teng CT. Detection of exon polymorphisms in the human lactoferrin gene. Biochem Cell Biol. 2002;80:17-22.
35. Luczak MW, Jagodziński PP. The role of DNA methylation in cancer development. Adv Cancer Res. 1990;54:1-23.
36. World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer. 2014; Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed August 8, 2014.
37. Poullis A, Foster R, Shetty A, etal. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13:279-284.
38. Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev. 2003;12:391-400.
39. Tanaka T, Kawabata K, Kohno H, etal. Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Jpn J Cancer Res. 2000;91:25-33.
40. Norrby K, Mattsby-Baltzer I, Innocenti M, etal. Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int J Cancer. 2001;91:236-240.
41. Chandra Mohan KV, Kumaraguruparan R, Prathiba D, etal. Modulation of xenobiotic-metabolizing enzymes and redox status during chemoprevention of hamster buccal carcinogenesis by bovine lactoferrin. Nutrition. 2006;22:940-946.
42. Ushida Y, Sekine K, Kuhara T, etal. Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. Jpn J Cancer Res. 1999;90:262-267.
43. Teraguchi S, Wakabayashi H, Kuwata H, etal. Protection against infections by oral lactoferrin: evaluation in animal models. Biometals. 2004;17:231-234.
44. Suzuki YA, Shin K, Lönnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry. 2001;40:15771-15779.
45. Yang N, Lejon T, Rekdal O. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci. 2003;9:300-311.
46. Fillebeen C, Descamps L, Dehouck MP, etal. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem. 1999;274:7011-7017.
47. Eliassen LT, Berge G, Leknessund A, etal. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer. 2006;119:493-500.
48. Yamada Y, Sato R, Kobayashi S, etal. The antiproliferative effect of bovine lactoferrin on canine mammary gland tumor cells. J Vet Med Sci. 2008;70:443-448.
49. Wolf JS, Li G, Varadhachary A, etal. Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clin Cancer Res. 2007;13:1601-1610.
50. Xu XX, Jiang HR, Li HB, etal. Apoptosis of stomach cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. J Dairy Sci. 2010;93:2344-2350.
51. Lin TY, Chiou SH, Chen M, etal. Human lactoferrin exerts bi-directional actions on PC12 cell survival via ERK1/2 pathway. Biochem Biophys Res Commun. 2005;337:330-336.
52. Lee SH, Park SW, Pyo CW, etal. Requirement of the JNK-associated Bcl-2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. Biochimie. 2009;91:102-108.
53. Fischer R, Debbabi H, Dubarry M, etal. Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. Biochem Cell Biol. 2006;84:303-311.
54. Iigo M, Shimamura M, Matsuda E, etal. Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa: a possible explanation for inhibition of carcinogenesis and metastasis. Cytokine. 2004;25:36-44.
55. Iigo M, Alexander DB, Long N, etal. Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie. 2009;91:86-101.
56. Kuhara T, Iigo M, Itoh T, etal. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer. 2000;38:192-199.
57. Rochard E, Legrand D, Lecocq M, etal. Characterization of lactotransferrin receptor in epithelial cell lines from non-malignant human breast, benign mastopathies and breast carcinomas. Anticancer Res. 1992;12:2047-2051.
58. Bi BY, Liu JL, Legrand D, etal. Internalization of human lactotransferrin by the Jurkat human lymphoblastic T-cell line. Eur J Cell Biol. 1996;69:288-296.
59. Duchardt F, Ruttekolk IR, Verdurmen WP, etal. A cell-penetrating peptide derived from human lactoferrin with conformation-dependent uptake efficiency. J Biol Chem. 2009;284:36099-36108.
60. Damiens E, Mazurier J, el Yazidi I, etal. Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. Biochim Biophys Acta. 1998;1402:277-287.
61. Ji ZS, Mahley RW. Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arterioscler Thromb. 1994;14:2025-2031.
62. Liu Y, Han F, Xie Y, etal. Comparative antimicrobial activity and mechanism of action of bovine lactoferricin-derived synthetic peptides. Biometals. 2011;24:1069-1078.
63. Yang N, Stensen W, Svendsen JS, etal. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J Pept Res. 2002;60:187-197.
64. Jin Y, Hammer J, Pate M, etal. Antimicrobial activities and structures of two linear cationic peptide families with various amphipathic β-sheet and α-helical potentials. Antimicrob Agents Chemother. 2005;49:4957-4964.
65. Ellerby HM, Arap W, Ellerby LM, etal. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032-1038.
66. Szachowicz-Petelska B, Dobrzynska I, Sulkowski S, etal. Characterization of the cell membrane during cancer transformation. J Environ Biol. 2010;31:845-850.
67. Meng X, Riordan NH, Riordan HD, etal. Cell membrane fatty acid composition differs between normal and malignant cell lines. P R Health Sci J. 2004;23:103-106.
68. Fujita K, Matsuda E, Sekine K, etal. Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis. 2004;25:1961-1966.
69. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene. 2005;24:7391-7393.
70. Aoki H, Kang PM, Hampe J, etal. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem. 2002;277:10244-10250.
71. Kaushic C, Frauendorf E, Rossoll RM, etal. Influence of the estrous cycle on the presence and distribution of immune cells in the rat reproductive tract. Am J Reprod Immunol. 1998;39:209-216.
72. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117:1466-1476.
73. Artym J, Zimecki M, Paprocka M, etal. Orally administered lactoferrin restores humoral immune response in immunocompromised mice. Immunol Lett. 2003;89:9-15.
74. Wang WP, Iigo M, Sato J, etal. Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res. 2000;91:1022-1027.
75. Cao R, Farnebo J, Kurimoto M, etal. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 1999;13:2195-2202.
76. Okamoto I, Kohno K, Tanimoto T, etal. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. J Immunol. 1999;162:3202-3211.
77. Kanwar JR, Palmano KP, Sun X, etal. "Iron-saturated" lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol Cell Biol. 2008;86:277-288.
78. Tung YT, Chen HL, Yen CC, etal. Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor. J Dairy Sci. 2013;96:2095-2106.
79. Beard JL, Dawson H, Piñero DJ. Iron metabolism: a comprehensive review. Nutr Rev. 1996;54:295-317.
80. Valko M, Rhodes CJ, Moncol J, etal. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1-40.
81. Richardson DR, Kalinowski DS, Lau S, etal. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009;1790:702-717.
82. Massodi I, Thomas E, Raucher D. Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer. Molecules. 2009;14:1999-2015.
83. Roseanu A, Florian PE, Moisei M, etal. Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells. Biometals. 2010;23:485-492.
84. McKeown ST, Lundy FT, Nelson J, etal. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 2006;42:685-690.
85. Wang J, Li Q, Ou Y, etal. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res. 2011;34:987-995.
86. Wang J, Li Q, Ou Y, etal. Recombination adenovirus-mediated human lactoferrin cDNA inhibits the growth of human MCF-7 breast cancer cells. J Pharm Pharmacol. 2012;64:457-463.
87. Chen H, Qin Y, Zhang Q, etal. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur J Pharm Sci. 2011;44:164-173.
88. Macciò A, Madeddu C, Gramignano G, etal. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist. 2010;15:894-902.
89. Beljaars L, Bakker HI, van der Strate BW, etal. The antiviral protein human lactoferrin is distributed in the body to cytomegalovirus (CMV) infection-prone cells and tissues. Pharm Res. 2002;19:54-62.
90. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592-599.